A major investigation is underway after counterfeit Abhayrab rabies vaccine vials, bearing genuine batch numbers, were seized from an unlicensed facility in Delhi.
- Counterfeit Abhayrab rabies vaccine vials were seized from an unlicensed residential premises in Mukherjee Nagar, Delhi.
- The Central Drugs Laboratory (CDL), Kasauli, declared the samples as 'Not of Standard Quality' and 'misbranded'.
- The suspect vials used the genuine batch number KE25012.
- Manufacturer Indian Immunologicals Ltd (IIL) has denied involvement in manufacturing the seized products.
In the fight against rabies, the margin for error is non-existent. A recent discovery involving counterfeit Abhayrab rabies vaccine vials has sent shockwaves through the medical community. During a joint enforcement operation by the Delhi Police Crime Branch and the Delhi Drugs Control Department, vials were recovered from an unlicensed premises in Mukherjee Nagar, Delhi. These vials, which bore the legitimate batch number KE25012, have been flagged as a severe public health risk.
The Central Drugs Laboratory (CDL) in Kasauli conducted rigorous testing and concluded that the seized samples were 'Not of Standard Quality' (NSQ) and 'misbranded'. The most alarming aspect of this investigation is the potential for these products to have reached unsuspecting patients. Since rabies is almost invariably fatal once symptoms appear, the administration of a non-potent vaccine creates a lethal illusion of protection.
Why This Matters
BozokMedia analysis shows that counterfeit medical products represent one of the most sophisticated threats to global health security. When life-saving vaccines like Abhayrab are falsified, the danger isn't just the loss of money, but the systematic erosion of immunity in vulnerable populations, potentially leading to preventable outbreaks.
A counterfeit vaccine is more dangerous than no vaccine at all, as it provides a false sense of security that delays life-saving medical intervention.
Indian Immunologicals Ltd (IIL), the manufacturer of Abhayrab via its Human Biologicals Institute (HBI), has proactively distanced itself from the counterfeit batch. IIL stated that their genuine batch KE25012, consisting of 83,370 vials, was released on November 7, 2025, following strict quality protocols. Laboratory analysis revealed 17 distinct differences between the counterfeit vials and the genuine reference samples, ranging from packaging and labeling to QR-code verification and cap color.
Historical Background
This is not an isolated incident in the pharmaceutical landscape. In 2025, a suspected counterfeit episode involving batch KA24014 prompted international health warnings. While that incident had global implications for travelers, the Central Drugs Standard Control Organisation (CDSCO) has confirmed that no part of the current KE25012 batch was exported, suggesting this specific counterfeit operation may be localized within India.
| Feature | Genuine Abhayrab | Seized Counterfeit |
|---|---|---|
| Batch Number | KE25012 | KE25012 (Impersonated) |
| Quality Status | Standard Quality | Not of Standard Quality (NSQ) |
| Key Discrepancies | Verified QR & Packaging | 17 differences identified |
| Source | Authorized Network | Unlicensed Premises |
Frequently Asked Questions
1. Is the original Abhayrab vaccine safe to use?
Yes, the manufacturer maintains that the legitimate KE25012 batch passed all mandatory potency tests and is safe.
2. How can I identify a fake vaccine?
Always ensure vaccines are obtained through authorized medical channels and check for intact, official packaging and verifiable QR codes.
